Effect of troglitazone on body fat distribution in type 2 diabetic patients

Diabetes Care

Volumn 22, Issue 6, 1999, Pages 908-912

  Mori, Yutaka ^a   Murakawa, Yuichi ^a   Okada, Kazuhisa ^a   Horikoshi, Hiroyoshi ^b   Yokoyama, Junichi ^d   Tajima, Naoko ^d   Ikeda, Yoshio ^c  

^a Kawachi gun   (Japan)

^b Research Inst   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; VISCERA;

ABDOMEN; ADIPOSE TISSUE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE TOLERANCE TEST; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; SKIN; THIAZOLES; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED; VISCERA;

EID: 0032969421     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.6.908     Document Type: Article

References (23)

1. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatu Y, Iwatsuka H, Suzuoki Z: Regulation of insulin resistance in obese and / or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2. 4-dione(ADD-3,878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32:804-810, 1983
2. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045 studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
3. Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH, Gibbs EM, Kreutter DK: Actions of a novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes 39:1218-1227, 1990
4. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
5. Horikoshi H, Yoshioka T: Troglitazone: a novel antidiabetic drug for treating insulin resistance. DDT 3:79-88, 1998
6. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P, for the Troglitazone study group: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39:701-709, 1996
7. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Sigeta Y, Kaneko T: Effect of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19:151-156, 1996
8. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
9. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956, 1995
10. Ohsumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioka S, Fujiwara T, Horikosi H, Serizawa N: Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 135:2279-2282, 1994
11. Szalkowski D, White-Carrington S, Berger J, Zhang B: Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136:1474-1481. 1995
12. Lambe KG, Tugwood JD: A human peroxisome-proliferator-activated receptor γ is activated by inducers of adipogenesis, including thiazolidmedione drugs. Eur J Biochem 239:1-7, 1996
13. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195, 1996
14. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668, 1996
15. Adams M, Montague CT Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazer MA, Chatterjee VKK, O'Rahilly S: Activators of peroxisome proliferator-activated receptor-γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997
16. Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S: A novel technique for the determination of body fat by computed tomography. Int J Obes 7:437-445, 1983
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
18. Mori Y, Murakawa Y, Okada K, Yokoyama J, Tajima N, Ikeda Y: Improvement of β-cell function with long-term treatment of acarbose or metformin in NIDDM. In Recent Advances on the Pathogenesis and Management of Diabetes Mellitus. Shinn SP, Shichiri M, Kom K-W, Eds. Amsterdam, Elsevier Science, 1998, p. 70-73
19. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikosi H, Yaazaki Y, Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
20. Katoh S, Mori Y, Yokoyama J, Tajima N, Ikeda K: Effect of long-term acarbose and glibenclamide treatment on visceral fat accumulation in patients with NIDDM (Abstract). Diabetologia 39 (Suppl 1):44A, 1996
21. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91, 1996
22. Cohen B, Novick D, Rubinstein M: Modulation of insulin activities by leptin. Science 274:1185-1188, 1996
23. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S: Contribution of intra-abdominal fat accumulation to the impairment of glucose an lipid metabolism in human obesity Metabolism 36:54-59, 1987